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Abstract: Cholesterol dysregulation has been implicated in age-related macular degeneration 
(AMD), the most common cause of visual impairment in the elderly. The 18 KDa translocator pro-
tein (TSPO) is a mitochondrial outer membrane protein responsible for transporting cholesterol 
from the mitochondrial outer membrane to the inner membrane. TSPO is highly expressed in ret-
inal pigment epithelial (RPE) cells, and TSPO ligands have shown therapeutic potential for the 
treatment of AMD. Here, we characterized retinal pathology of Tspo knockout (KO) mice using 
histological, immunohistochemical, biochemical and molecular biological approaches. We found 
that Tspo KO mice had normal retinal morphology (by light microscopy) but showed elevated 
levels of cholesterol, triglycerides and phospholipids with perturbed cholesterol efflux in the RPE 
cells of Tspo KO mice. Expression of cholesterol-associated genes (Nr1h3, Abca1, Abcg1, Cyp27a1 
and Cyp46a1) was significantly downregulated, and production of pro-inflammatory cytokines 
was markedly increased in Tspo KO retinas. Furthermore, microglial activation was also observed 
in Tspo KO mouse retinas. These findings provide new insights into the function of TSPO in the 
retina and may aid in the design of new therapeutic strategies for the treatment of AMD. 
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1. Introduction 
Age-related macular degeneration (AMD) is the most frequent condition leading to 
legally defined blindness among senior citizens. In early stages of the disease, AMD 
patients may encounter no or limited vision loss. Unfortunately, as the disease pro-
gresses, they may experience the total loss of central vision, finally resulting in complete 
blindness. In practice, patients may discern no significant disturbance to peripheral vi-
sion, but the condition can have an adverse effect on their ability to read or drive [1]. The 
disease is seldom detected in people under 50 years of age, but the prevalence rises with 
aging, with 60% of people over the age of 90 affected by AMD [2,3]. Late AMD is divided 
into two subgroups: dry (geographic atrophy, accounting for 90% of AMD) and wet 
(neovascular) AMD. Anti-vascular endothelial growth factor (VEGF) drugs demonstrate 
protective effect in treating wet AMD. However, there is no effective treatment for dry 
AMD patients [4]. 
The generation of superfluous energy associated with abnormal lipid metabolism 
can cause dyslipidaemia, which is a crucial precursor to cardiovascular disease, obesity 
and cholestasis [5]; it also constitutes a significant risk factor for the advancement of 
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AMD [6]. Cholesterol, the principal sterol, accumulates in deposits known as drusen, in 
the retinas of AMD patients [7,8]. In addition, a diet rich in cholesterol and saturated fat 
constitutes a high risk for development of AMD [9]. Certain genetic variants of choles-
terol homeostasis genes are often associated with AMD [10]. Preclinical examination 
demonstrates that lipid dysregulation can boost the progress of AMD lesions in animal 
models which replicate certain phenotypes of AMD [11,12]. 
Translocator protein (TSPO) was initially identified in 1977 as a peripheral benzo-
diazepine receptor [13]. TSPO is a 169-amino acid protein localized to the outer mito-
chondrial membrane and is encoded by a nuclear gene containing four exons [14]. TSPO 
contains five α-helical transmembrane domains and includes a cholesterol-recognition 
amino acid consensus (CRAC) sequence at its C-terminus which bends toward the lipid 
membrane [15]. TSPO is thought to be involved in mitochondrial transition pore regula-
tion, steroid synthesis, Ca2+ homeostasis, the generation of reactive oxygen species and 
the production of energy from nutrients [14,16]. Following identification of TSPO as a 
peripheral binding site for benzodiazepines, TSPO ligands were investigated as possible 
treatments for psychiatric disorders. Indeed, these ligands brought about positive results 
for anxiety maladies in animals and human subjects [14,17]. It has been postulated that 
TSPO ligands increase levels of (neuro)steroids, such as allopregnanolone, and as a con-
sequence, moderate the activity of GABAA [17]. TSPO is highly expressed in steroido-
genic tissues including the gonads, adrenal glands and the cerebrum [16]. Accordingly, 
the major function of TSPO is mitochondrial cholesterol trafficking, transporting choles-
terol from the mitochondrial outer membrane to the inner membrane, where cholesterol 
is metabolized into steroids in steroid-generating cells or oxysterols in nonsteroidogenic 
cells [18]. 
Our previous studies demonstrated that TSPO is expressed at high levels in the 
retinal pigment epithelial (RPE) and choroidal endothelial cells and regulates cholesterol 
efflux [18,19]. Aging mice exhibit decreased expression of Tspo and reduced cholesterol 
efflux in the RPE cells. TSPO deletion leads to increased uptake and accumulation of 
oxidized low-density lipoprotein (LDL), and higher production of reactive oxygen spe-
cies and proinflammatory cytokines [18]. Additionally, we found that TSPO ligands 
promoted cholesterol efflux in RPE and choroidal endothelial cells and decreased lipo-
genesis [18,19]. A TSPO ligand, etifoxine, also decreased serum and RPE cholesterol in 
mice fed with a high-fat diet and lowered inflammatory cytokines in serum and the RPE 
[20,21]. In this work, we have characterized the Tspo knockout (KO) mice, specifically 
examining retinal histology and cholesterol homeostasis during aging. 
2. Materials and Methods 
2.1. Animals 
All animal work was carried out in compliance with the Animal Ethics and Welfare 
Committee, Glasgow Caledonian University, and the UK Home Office under a Project 
License PPL 60/4347. The Tspo floxed (wildtype, WT) and Tspo knockout (KO) mice were 
gifted from Dr. Vimal Selvaraj (Cornell University) [22,23]. All animals were housed 
under a standardized light–dark cycle and all efforts were applied to use a minimum 
number of animals and to ensure minimum suffering. 
2.2. Genotyping 
DNA was extracted from mouse ear notch and dissolved in sterile dH2O. Polymer-
ase chain reaction (PCR) was performed by using the DreamTaq PCR Reddy Master mix 
(Thermo Fisher Scientific, Paisley, UK), following the manufacturer’s protocol. Each PCR 
reaction contained 25 µL DreamTaq PCR Reddy Master mix, 1 µL, 100 µM of forward 
(5′TCACCAAGGGTGTGAATGAA3′) and reverse (5′AACCTACCTGGTGGCTTCCT3′) 
primers, 1 µL mouse DNA and 22 µL of nuclease-free water. The thermo-cycle program 
Cells 2021, 10, 3066 3 of 16 
 
 
for PCR is 94 °C for 3 min, 40 cycles of 94 °C for 15 sec, 60 °C for 15 sec and 72 °C for 1 min 
10 sec, and 72 °C for 7 min. The PCR products were separated in 1% agarose gel. 
2.3. Western Blotting 
Brain, retinas and RPE/choroid/sclera were dissected from wildtype and Tspo KO 
mice, then homogenized in cold T-PER reagent (Thermo Fisher Scientific, Paisley, UK). 
The tissue lysates were centrifuged at 10,000× g for 10 min. The supernatants were col-
lected and the concentration was measured. Then, 50 µg proteins from each sample were 
separated by sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) 
and transferred into nitrocellulose membrane. The membrane was initially blocked with 
5% non-fat dry milk powder in PBS, then incubated with primary antibodies and corre-
sponding secondary antibodies respectively. Targeted protein signals were detected us-
ing the LI-COR Odyssey FC Imaging System. 
2.4. Haematoxylin and Eosin Staining (H&E) 
Mouse eyes were fixed with 4% paraformaldehyde (PFA) in phosphate-buffered sa-
line (PBS) (Thermo Fisher Scientific, Paisley, UK), then washed by PBS twice, followed by 
dehydration through 5%, 15% and 30% sucrose. The eye samples were embedded in Op-
timal Cutting Temperature (OCT) compound (VWR, Lutterworth, UK) and cut into 8 
μm–10 μm thickness. The cryosections were further fixed by 100% cold methanol for 30 
min at −20 °C. The slides were stained with hematoxylin (Sigma, Dorset, UK) for 8 min, 
then washed for 20 min with running tap water and rehydrated through 50% ethanol for 
2 min and 70% ethanol for 2 min, finally counterstained by Eosin (Sigma, Dorset, UK) for 
1 min. The slides were further dehydrated by passing through 90% ethanol for 1 min and 
100% ethanol for 5 min. Slides were photographed under light microscope (Olympus, 
Essex, UK). For measuring the thickness of the retinal outer nuclear layer (ONL), two 
retinal sections from each eye were chosen and images were captured from the superior 
and inferior sides of the optic nerve head; the thickness of ONL was measured at inter-
vals of 200 µm. Four eyes from four individual animals of wildtype or Tspo KO group 
were used for the measurement. 
2.5. Immunohistochemistry 
Mouse eye cryosections were air-dried for 10 min and rehydrated by washing buffer 
(0.025% Triton X-100 in 1×TBS) two times (5 min each time), then blocked with blocking 
buffer (0.3% Triton X-100/5% sheep serum in 1×TBS) for 1 h at room temperature. The 
sections were incubated with anti-Iba-1 primary antibody in blocking buffer overnight at 
4 °C, washed 3 times by washing buffer (5 min each), followed by incubation with AF488 
secondary antibody (Thermo Fisher Scientific, Paisley, UK) for 1 h at room temperature. 
Slides were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher 
Scientific, Paisley, UK) after being washed 5 times (5 min each) using washing buffer. 
Images were taken under confocal microscopy. Intensity of microglia in ONL was quan-
tified following our previous description [24]. 
2.6. Measurement of Cholesterol Efflux in Mouse Primary Retinal Pigment Epithelium (RPE) 
Cells 
Mouse primary RPE cells were isolated from WT and Tspo homozygous KO mice 
according to our previous description [18]. Isolated RPE cells were seeded on 12-well 
plates and labelled with [3H]cholesterol for 24 h with 2% bovine serum albumin in se-
rum-free culture media. Efflux was initiated by the addition of serum-free DMEM/F12 
containing apolipoproteins A-I (ApoA-I, 10 mg/mL), high-density lipoprotein (HDL, 20 
mg/mL) or human serum (1%, v/v) and cultured for 24 h. Cholesterol efflux was then 
calculated as an expression of percentage of cholesterol efflux to each of the acceptors as 
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follows: % efflux = (disintegrations per minute (DPM) media/DPM Media + DPM Cells) × 
100. 
2.7. Gene Expression 
Total RNAs were extracted from brain, retina and RPE/choroid/sclera using Tri Re-
agent (Sigma, Dorset, UK), according to the manufacturer’s protocol. cDNAs were syn-
thesized using a High-Capacity cDNA Reverse Transcription Kit with RNAase inhibitor 
(Thermo Fisher Scientific), following the manufacturer’s guidance. Quantitative real-time 
polymerase chain reaction (qRT-PCR) was performed using a Platinum Syber Green 
QPCR Super Mix-UDG w/ROX kit (Thermo Fisher Scientific, Inchinnan, Scotland). 
Briefly, the reaction was carried out in triplicate in a 10 µL reaction volume containing 5 
µL of Syber Green mix, 2 µL of cDNA sample (~100 ng per 10 µL reaction), 0.2 µL of 10 
µM forward and reverse primers (Table S1) and 2.6 µL of nuclease-free water to quantify 
gene expression under the following temperature conditions: 50 °C for 2 min (UDG in-
cubation), followed by the enzyme activation step at 95 °C for 2 min and the amplifica-
tion step of 40 cycles including DNA denaturation at 95 °C for 15 s and primer annealing 
at 60 °C for 15 s. The quantification was performed on a Bio-Rad CFX96 Real-Time PCR 
Detection System (Bio-Rad, Watford, UK). The fluorescence signals were detected at the 
end of the 60 °C step and the assay validity was examined on the basis of the melting 
curve between 60 and 95 °C for 1 s per 1 °C, followed by each run. The relative expression 
of candidate genes was calculated based on the formula: 2-ΔΔCT, which was normalized by 
the housekeeping gene. 
2.8. Quantification of Total Cholesterol, Phospholipid and Triglyceride in Mouse Tissues 
Mouse tissues (brain, retina and RPE/choroid/sclera) were homogenized with a lipid 
extraction buffer: Hexane: isopropanol (3:2) and incubated for 30 min at room tempera-
ture. The organic solvents were centrifuged at 1500× g for 10 min and the supernatant 
was collected and dried at 50 °C. The dried solvent was dissolved with 1× reaction buffer. 
Total cellular cholesterol and phospholipid were measured using an Amplex®  Red Cho-
lesterol Assay Kit (Alfa Aesar, Heysham, UK) and a Phospholipid Assay Kit (Sigma, 
Dorset, UK), respectively, according to the manufacturer’s guidance. For measurement of 
triglyceride, mouse tissues were homogenized in buffer containing 5 volumes of iso-
propanol, 2 volumes of water and 2 volumes of Triton X-100 and centrifuged for 4 min at 
13,000 rpm. The supernatants were collected and subjected to triglyceride measurement 
using an EnzyChrom Triglyceride assay kit (BioAssay system, Hayward, USA), accord-
ing to the manufacturer’s protocol. 
2.9. Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA was performed to determine the concentration of IL-1β, IL-6 and TNFa in 
wildtype and Tspo KO mouse tissues. The IL-1 β, IL-6 and TNFa ELISA kits were pur-
chased from PeproTech, UK. The ELISA assay for IL-1β, IL-6 and TNFa was performed in 
a Nunc-Immuno™ MicroWell™ 96-well solid plate (Sigma, Dorset, UK), according to the 
manufacturer’s protocol. In brief, the plate was coated with the captured antibody (100 
µL/well, 3 µg/mL) and incubated overnight at room temperature. The uncaptured anti-
body was aspirated and the plate was washed 4 times with the washing buffer. The plate 
was incubated with the blocking buffer (300 µL/well) for 2 h at room temperature, then 
washed 4 times with the washing buffer. Further, 100 µL/well of working standard solu-
tion of IL-1β, IL-6 and TNFa (0, 10, 100, 1000 pg/mL) and 100 µL/well of unknown sam-
ples (tissue extraction) were added, and the plate was incubated at room temperature for 
2 h. All liquid was removed and the plate was washed 4 times with the washing buffer. 
The plate was incubated with respective antibodies, incubated at room temperature for 2 
h, then washed 4 times with the washing buffer. The plate was incubated with Avi-
din-HRP conjugate (100 µL/well, 1.25 µg/mL) in darkness at room temperature for 45 
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min. The unbound Avidin-HRP conjugate was aspirated and the plate was washed 4 
times with the washing buffer. Finally, the plate was incubated with 100 µL/well of ABTS 
Liquid Substrate (Sigma, Dorset, UK), and the color change was monitored every 5 min 
for a period of 30 min. The absorbance (OD) was measured at 405 nm with wavelength 
correction set at 650 nm. The standard curve was constructed on the basis of the mean 
absorbance for each standard concentration (X axis) against the target standard concen-
tration (Y axis). The concentration of unknown samples (pg/mL) was calculated based on 
the straight-line equation obtained from the linear-regression trendline according to Y = 
mX + c (where Y = OD of unknown sample, m = the slope value, X = the concentration of 
unknown sample and c = intercept). All experiments were repeated 3 times in triplicate. 
2.10. Statistical Analysis 
Data were analyzed by statistical significance using analysis of variance (ANOVA) 
and t-test; after that, appropriate post hoc tests (Bonferroni) using Prism software (ver-
sion 6.0 from GraphPad Software Inc., San Diego, CA, USA) were conducted. All data 
were from a minimum of three independent experiments in triplicate unless otherwise 
stated. The data are presented as mean ± SD. p < 0.05 means significant. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
3. Results 
3.1. Confirmation of TSPO Deletion 
Previously, Tspo KO mice were generated by deletion of exons 2 and 3 of Tspo gene 
[22]. To genotype Tspo KO mice, primers flanking exons 2 and 3 were used. We amplified 
a 2697bp fragment in WT and a fragment of 872bp fragment in KO mice as predicted 
(Figure S1A). Further, we examined TSPO protein in mouse tissues by Western blot. We 
found that WT mouse RPE/choroid/sclera expressed high levels of TSPO protein, with 
lower levels found in the neural retinas (Figures S1B and S2A), consistent with our pre-
vious report [18]. However, we did not detect TSPO protein in WT mouse brain (Figures 
S1C and S2B), though Betlazar et al. (2018) reported low levels of TSPO expression in 
mouse brain detected as by immunohistochemistry [25]. It is possible that low levels of 
TSPO protein in the whole brain lysates are undetectable by Western blot. 
3.2. No Morphological Changes in Tspo KO Retinas 
To assess whether TSPO deletion affects retinal structure, we performed Haema-
toxylin and Eosin staining on cryosections of eyes from Tspo KO and WT mice at 6, 12 and 
18 months old (Figure 1). No gross morphological differences between WT and Tspo KO 
mouse retinas were observed by light microscopy. To investigate if there was any pho-
toreceptor loss, we measured the thickness of the outer nuclear layer at five different 
points along the superior and inferior regions of the retinas in WT and Tspo KO mice. No 
significant difference in the thickness of outer nuclear layer between WT and Tspo KO 
mice was observed at all age points (Figure 1). 




Figure 1. Retinal morphology in WT and Tspo KO mice. Histological examination with haematoxylin and eosin staining 
showing normal retinal morphology and no significant difference in thickness of outer nuclear layer (ONL) in WT and 
Tspo KO mice at 6 (A), 12 (B) and 18 mon (C) of age. Graphs show the thickness of ONL on both the superior (Sup) and 
inferior (Inf) sides of the retina (n = 5). INL: inner nuclear layer; IPL: inner plexiform layer; ONH: optic nerve head; ONL: 
outer nuclear layer; OPL: outer plexiform layer; RPE: retinal pigment epithelial cells. Data were collected from three in-
dependent experiments and analyzed by two-way ANOVA followed by Bonferroni test: NS: no significance; ***p < 0.001, 
****p < 0.0001. Scale bar, 10 µm. 
3.3. Cholesterol Efflux Reduced in Tspo KO Mouse RPE Cells 
Our previous study demonstrated that loss of TSPO in human RPE cells resulted in 
cholesterol efflux defects [18]. Next, we examined the effect of TSPO deletion on choles-
terol efflux in mouse primary RPE cells. We observed that the percentage of 
[3H]cholesterol efflux to apoA-I, HDL, or human serum was significantly decreased in 
Tspo KO mouse RPE cells when compared to that of WT RPE cells (Figure 2). 




Figure 2. Decreased cholesterol efflux in Tspo KO mouse RPE cells. Primary RPE cell derived from wildtype (WT) and 
Tspo KO mice at 6 months old were labelled with 0.5 lCi/mL [3H]cholesterol for 24 h followed by 24 h incubation with or 
without apolipoproteins A–I (ApoA-I, 10 μg/mL), HDL (20 μg/mL) and human serum (HS, 1% v/v). After incubation, the 
percentage of [3H]cholesterol efflux was measured. Data were collected from three independent experiments and ana-
lyzed by two-way ANOVA followed by Bonferroni test: NS: no significance; ***p < 0.001, ****p < 0.0001. 
3.4. Increased Lipid Accumulation in Tspo KO Mouse Tissues 
Previously, we reported that loss of TSPO caused accumulation of intracellular oxi-
dized LDL in human RPE cells [18]. Here, we measured cholesterol mass, triglycerides 
and phospholipids in RPE/choroid/sclera, retina and brain of WT and Tspo KO mice at 
the ages of 6, 12 and 18 months. The contents of cholesterol, triglycerides and phospho-
lipids in RPE/choroid/sclera of Tspo KO mice were significantly increased compared to 
that of WT mice (Figure 3A). In Tspo KO retinas, cholesterol levels were significantly 
higher at 6 and 12 months old but not at 18 months old when compared to that of WT 
mice. Triglyceride levels in Tspo KO retinas were notably increased at all age points when 
compared to that of WT animals. Phospholipids in Tspo KO retinas were only signifi-
cantly increased at the age of 6 months when compared to WT animals (Figure 3B). Sim-
ilar observations were seen in Tspo KO brains. Cholesterol levels in Tspo KO brains were 
significantly increased at 6 and 18 months old but not at 12 months old, compared to that 
of WT animals. Both triglycerides and phospholipids were significantly higher in Tspo 
KO brains at all ages when compared to those of WT mice (Figure 3C). 




Figure 3. Total cholesterol, Triglycerides and phospholipids in RPE/choroid/sclera (A), retina (B) and brain (C) brain of 
wildtype and Tspo KO mice (6, 12 and 18 months old) were measured and normalized to total protein contents. Data were 
collected from three independent experiments and analyzed by two-way ANOVA followed by Bonferroni test. NS: no 
significance; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
3.5. Deletion of TSPO Decreased Expression of Cholesterol Homeostasis Genes 
Since deletion of TSPO caused cholesterol efflux defects in RPE cells and increased 
cholesterol levels in RPE/choroid/sclera, retinas and brains (Figures 2 and 3), we exam-
ined expression of genes associated with cholesterol metabolism and trafficking. The 
expression of Nr1h3 (encoding liver X receptor alpha, LXRa), Abca1, Abcg1, Cyp27a1 and 
Cyp46a1 was significantly downregulated in the RPE/choroid/sclera and retina of Tspo 
KO mice at 6, 12 and 18 months old compared to WT mice (Figure 3A,B). Similarly, ex-
pression of these genes was markedly decreased in brains of Tspo KO mice at the ages of 
6, 12 and 18 months compared to that of WT mice (Figure 4C). 




Figure 4. The expression of cholesterol homeostasis genes: Nr1h3, Abca1, Abcg1, Cyp27a1 and Cyp46a1 in 
RPE/choroid/sclera (A), retina (B) and brain (C) of wildtype (WT) and Tspo KO mice at 6, 12 and 18 months old. The 
qRT-PCR data were collected as ct (Cycle threshold) values and normalised to Gapdh then analyzed by 2−ΔΔCT formula. The 
fold changes of each gene were presented as means ± SD and analyzed by two-way ANOVA with the appropriate post 
hoc test Bonferroni multiple comparisons tests (n = 5). ***p < 0.001, ****p < 0.0001. 
3.6. Deletion of TSPO Increased Inflammation in The Tissues of Tspo KO Mice 
Since increased inflammation was observed in human RPE cells with TSPO deletion 
[18], we examined the expression of inflammatory genes, Tnfa, Il-1β and Il-6, in 
RPE/choroid/sclera, retina and brain of WT and Tspo KO mice at 6, 12 and 18 months old. 
The mRNA levels of these genes were markedly higher in RPE/choroid/sclera, retina and 
brain of Tspo KO mice compared to that of WT mice (Figure 5). We also measured TNFα, 
IL-1β and IL-6 protein by ELISA and found that levels of these inflammatory cytokines 
were significantly increased in RPE/choroid/sclera, retina and brain of Tspo KO mice at 6, 
12 and 18 months old compared to that of WT mice (Figure 6) 




Figure 5. The expression of inflammation genes, Tnfa, Il-1β and Il-6, in RPE/choroid/sclera (A), retina (B) and brain (C) of 
WT and Tspo KO mice at the ages of 6, 12 and 18 months. The qRT-PCR data were collected as ct (cycle threshold) values 
and normalised to Gapdh, then analyzed by 2−ΔΔCT formula. The fold changes of each gene were presented as means ± SD 
and analyzed by two-way ANOVA with the appropriate post hoc test Bonferroni multiple comparisons tests (n = 5). *p < 
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 




Figure 6. The levels of the inflammatory cytokines: TNFα, IL-1β and IL-6, in RPE/choroid/sclera (A), retina (B) and brain 
(C) of WT and Tspo KO mice at the ages of 6, 12 and 18 months. The data were presented as means ± SD and analyzed by 
two-way ANOVA with the appropriate post hoc test Bonferroni multiple comparisons tests (n = 5). *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001. 
3.7. Microglial Activation in Tspo KO Mouse Retina 
Microglia are resident macrophages in the central nervous system, including the 
retina, where microglia can be activated under stress/pathological conditions [26]. TSPO 
is thought to mediate neuroinflammation, including microglial activation [16]. To ex-
amine whether there is microglial activation in Tspo KO mouse retinas, a biomarker 
(Iba-1) for microglia was detected by immunohistochemistry in cryosections from WT 
and Tspo KO mouse eyes. We observed that microglia were activated and migrated into 
the outer nuclear layer of Tspo KO retinas at the ages of 6, 12 and 18 months; however, in 
WT retinas, microglia were restricted to outer and inner plexiform layers (Figure 7). 
TMEM119 is another microglial biomarker, expressed at a higher level in rd1 mouse 
retina compared to that of WT mice [27]. We measured Tmem119 mRNA in the 
RPE/choroid/sclera and retinas of WT and Tspo KO mice at 6, 12 and 18 months old, 
demonstrating that expression of Tmem119 in Tspo KO RPE/choroid/sclera and retinas 
was significantly increased when compared to that of WT mice (Figure S3). 




Figure 7. Microglia in the retinas of wiltype and Tspo KO mice at the ages of 6 (A), 12 (B) and 18 (C) months. Im-
munostaining of microglia marker: Iba-1 (green), was performed with cryosections from wildtype and Tspo KO mouse 
eyes. The intensity of microglia in the outer nuclear layer was quantified. Data were analyzed by t-test followed by Bon-
ferroni test (n = 5). INL: inner nuclear layer; IPL: inner plexiform layer; ONH: optic nerve head; ONL: outer nuclear layer; 
OPL: outer plexiform layer; RPE: retinal pigment epithelial cells. ****p < 0.0001. Scale bar, 10 µm. 




As a multiple-function protein, TSPO was initially thought to play a critical role in 
steroidogenesis, via transporting cholesterol from the mitochondrial outer membrane to 
the inner membrane, where cholesterol is cleaved by CYP11A1 to produce pregneolone, 
the precursor of steroids. Early work demonstrated that TSPO ligands promote steroid 
generation and knockdown or disruption of TSPO decreases production of steroid hor-
mone [28–31]. However, some recent work related to TSPO-associated steroidogenesis is 
controversial. Data from Dr. Selvaraj’s lab demonstrated that global or conditional 
knockout of Tspo in mice had no effect on steroid production [22,24]. Data from Drs. Pa-
padopoulos and Higuchi’s laboratories showed that global or conditional deletion of 
TSPO in mice resulted in steroidogenic abnormalities [32–34]. Owen et al. reported that 
knockout of Tspo in rats also caused impaired steroid synthesis, and humans carrying the 
rs6971 polymorphism (Ala147Thr) had decreased adrenocorticotropic hormone-induced 
corticosteroid levels [35]. The inconsistent results from individual studies are possibly 
due to different genetic backgrounds or approaches to create the KO lines. 
We were the first to investigate TSPO function in the retinas, demonstrating that 
TSPO is expressed at high levels in human and mouse RPE cells, and its expression is 
markedly decreased in aged-mouse RPE. We also found that TSPO mediated mitochon-
drial cholesterol efflux in RPE cells and that deletion of TSPO resulted in cholesterol ef-
flux defects and accumulation of cholesterol [18]. Here, Tspo knockout mouse RPE cells 
also showed impaired cholesterol efflux (Figure 2). There were also significantly higher 
levels of cholesterol, triglycerides and phospholipids and downregulation of cholesterol 
homeostasis genes in Tspo KO RPE/choroid/sclera, retina and brain (Figures 3 and 4), 
suggesting that TSPO mediates cholesterol metabolism and transport in the central 
nervous system. 
TSPO deletion in human RPE cells caused increased uptake and accumulation of 
oxidized LDL, which induced inflammation [18]. Accumulated cholesterol can be oxi-
dized to form oxysterols, some of which, such as 7-ketocholesterol, are toxic and induce 
inflammation and angiogenesis. 7-ketocholesterol is commonly presented in oxidized 
LDL, both 7-ketocholesterol and oxidized LDL are enriched in drusen, a key clinical 
feature of AMD [36]. TSPO ligands also suppressed production of inflammatory cyto-
kines (IL-1β, IL-6, TNFα and VEGF) induced by oxidized LDL in choroidal endothelial 
cells [19]. Actually, TSPO ligands have demonstrated protection in various neurodegen-
erative disorders by counteracting inflammation [37,38]. Tspo KO mouse 
RPE/choroid/sclera, retina and brain had higher expression (mRNA and protein) of in-
flammatory cytokines: IL-1β, IL-6 and TNFα (Figures 5 and 6). Elevated expression of 
these cytokines may be a direct result of cholesterol accumulation and its derived oxys-
terols, which warrants further investigation. 
Microglial activation plays an important role in the pathogenesis and progression of 
neurodegenerative diseases, including retinal degeneration [26]. TSPO stands out as a 
possible biomarker in the arena of neuroinflammation, with ligands under scrutiny at 
present in the arena of clinical neuroimaging [14]. However, the mechanism which im-
pels the upregulation of TSPO during the disorders remains ambiguous, as does the role 
of TSPO in the activation of microglia. TSPO ligand, XBD173, has been shown to inhibit 
microglial activation in a mouse microglial cell line and in living-mouse retinal explants, 
suppressing inflammation [39]. XBD173 also inhibited microglial activation and pre-
vented retinal degeneration in mice exposed to acute light damage [40]. We also found 
microglial activation in Tspo KO mouse retinas at the ages of 6, 12 and 18 months (Figure 
7); the underlying mechanism for the activation needs further attention. 
As a complex disease, the development of AMD pathology is poorly understood. It 
is believed that cholesterol homeostasis, extracellular matrix remodelling, complement 
activation and angiogenesis are involved in the pathogenesis and progression of AMD 
[4]. Although Tspo KO mice demonstrated some AMD pathological features such as 
cholesterol efflux defect, accumulation of cholesterol in the retina, increased inflamma-
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tion and microglial activation, the thickness of outer nuclear layer was not different be-
tween WT and Tspo KO mice even at the age of 18 months (Figure 1), suggesting no no-
table photoreceptor cell death in Tspo KO retinas. Further examination is required to ex-
plore whether there are any subtle pathological changes such as sub-RPE deposits and 
RPE atrophy in Tspo KO mouse retinas using transmission electron microscopy. The 
other possibility is that the retinal pathology in Tspo KO mice may develop much later. 
The complement factor h gene (CFH) is the major gene associated with AMD (Hageman 
et al., 2005; Haines et al., 2005; Klein et al., 2005) [41–43]. Cfh genetic altered mouse mod-
els are widely used to understand the pathological mechanisms of AMD. Cfh-/− mice only 
displays subtle retinal pathology such as increased subretinal autofluorescence and dis-
organized photoreceptor outer segments at the age of 24 months old [44]. However, Cfh-/− 
mice develop more dominant retinal phenotypes when fed with a high-fat diet [12,45]. 
So, it is necessary to further examine retinal pathology in Tspo KO mice fed with a 
high-fat diet. 
5. Conclusions 
The current study demonstrates that deletion of TSPO in mice resulted in cholesterol 
efflux defect in RPE cells, increased lipids (cholesterol, triglyceride and phospholipid) in 
the retinas, decreased expression of cholesterol-associated genes, increased inflamma-
tion, and microglial activation. We believe that further studies of Tspo KO mouse model 
will help to understand TSPO-associated function in the retina and to develop new 
treatment for AMD. 
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